A Phase 1/2 trial of SRA737 in subjects with advanced cancer
Research type
Research Study
Full title
A Phase 1/2 Trial: A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in subjects with advanced cancer.
IRAS ID
198451
Contact name
Udai Banerji
Contact email
Sponsor organisation
Sierra Oncology, Inc.
Eudract number
2015-004486-86
Duration of Study in the UK
1 years, 9 months, days
Research summary
This clinical study is looking at a drug called SRA737. This is a new drug which looks promising in laboratory studies. It was developed through a collaboration between The Institute of Cancer Research (ICR), part of the Royal Marsden Hospital in Sutton; Cancer Therapeutics Unit (CTU), Sareum Ltd and Cancer Research Technology Ltd (CRT). We now wish to find out if SRA737 will be useful in treating patients with cancer. This study is being sponsored by Sierra Oncology, Inc. (Sierra Oncology).
SRA737 is a type of drug called a kinase inhibitor. It blocks a chemical messenger (enzyme) called checkpoint kinase 1 (CHK-1) which is part of the signalling process within cells. This can make cells produce chemicals that trigger and control cell growth and cell death. In some types of cancer these chemical messengers are 'switched on' or ‘switched off’ allowing the cancer cells to keep growing and to grow more quickly than normal cells. Kinase inhibitors are a new type of drug being used to try to stop the growth of cancers and to kill cancer cells.
The main aims of this clinical study are to find out:
• The maximum dose that can be given safely to patients;
• More about the potential side effects of the drug and how they can be managed;
• What happens to drug inside the body; and
• Whether the drug has an effect on the cancer and whether the effect, if any, is related to specific changes in the tumour’s DNA.This information will help us decide how much and how often to give SRA737 to patients in future studies. It may also help us understand any effect the drug may have on cancer.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
16/LO/0423
Date of REC Opinion
25 Apr 2016
REC opinion
Further Information Favourable Opinion